A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study during which patients with advanced/metastatic solid tumors will
receive investigational study drug ARRY-334543 and capecitabine. Patients will receive
increasing doses of study drug in combination with capecitabine in order to achieve the
highest dose of study drug possible that will not cause unacceptable side effects. Patients
will be followed to see what side effects the combination causes and what effectiveness the
combination has, if any, in treating the cancer. Approximately 30 patients from the US and
Canada will be enrolled in this study.
Phase:
Phase 1
Details
Lead Sponsor:
Array BioPharma Array Biopharma, now a wholly owned subsidiary of Pfizer